Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TransMedics (TMDX) EPS (Weighted Average and Diluted) (2020 - 2026)

TransMedics has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at $2.59 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 1195.0% year-over-year to $2.59; the TTM value through Dec 2025 reached $4.87, up 377.45%, while the annual FY2025 figure was $4.87, 382.18% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $2.59 at TransMedics, up from $0.66 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $2.59 in Q4 2025 and troughed at -$0.78 in Q3 2023.
  • A 5-year average of $0.11 and a median of -$0.06 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 212.0% in 2023 and later skyrocketed 1266.67% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.46 in 2021, then surged by 56.52% to -$0.2 in 2022, then skyrocketed by 160.0% to $0.12 in 2023, then skyrocketed by 66.67% to $0.2 in 2024, then soared by 1195.0% to $2.59 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TMDX at $2.59 in Q4 2025, $0.66 in Q3 2025, and $0.92 in Q2 2025.